Drug discovery partnerships between UK CROs and the Swiss pharma sector

Pharmaceutical Technology Europe

Volumn 26, Issue 4, 2014, Pages 8-10

  Kermani, Faiz ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICINE; DRUG DEVELOPMENT; DRUG INDUSTRY; SHORT SURVEY; SWITZERLAND; TECHNOLOGY; UNITED KINGDOM;

EID: 84898489124     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. EFPIA, "The pharmaceutical industry in figures," www.efpia.eu/uploads/Figures-Key-Data-2013.pdf, accessed 5 March 2014.
2. ABPI, "Industry achievements," www.abpi.org.uk/industry-info/ achievements, accessed 5 March 2014.
3. R. Weaver, "XenoGesis: Discovery DMPK in the Rapidly Evolving R&D sector. Early stage drug discovery partnering with CROs from Nottingham, UK," presentation at UK Trade & Investment (Basel, Switzerland, 26 February 2014).
4. Visiongain, "The global drug discovery outsourcing market will reach $14.9BN in 2014," Press Release, 13 January 2014.
5. Research and Markets, "The New Trends of Global Drug Discovery Outsourcing 2013," www.researchandmarkets.com/research/4m6slf/the-new- trends-of, accessed 5 March 2014.
6. The Institute of Cancer Research, "Smarter drugs to outsmart cancer," instituteofcancerresearch.wordpress.com/tag/drug-attrition, accessed 5 March 2014.